Floatz logo

Alisertib

Recurrent Marginal Zone Lymphoma

Ohio State University Comprehensive Cancer CenterSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

106 Active assets in the Recurrent Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
VINCRISTINE SULFATE
Mayo Clinic
Phase 2BBB

View all 50 →

Same molecule, other indications

Alisertib is also rated in:

Burkitt lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
69 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →